Subscribe To

Price Alert Latest News Economic Calendar News

LVTX / LAVA Therapeutics to Present Updated LAVA-051 Clinical Data at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

UTRECHT, The Netherlands and PHILADELPHIA, April 27, 2022 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. ( Nasdaq: LVTX ), an immuno-oncology company focused on developing its proprietary Gammabody™ platform of bispecific gamma delta T cell engagers to transform the treatment of cancer, today announced the Company will present updated interim data from the dose escalation phase of the ongoing Phase 1/2a clinical trial of LAVA-051 in patients with relapsed or refractory chronic lymphocytic leukemia (CLL) and multiple myeloma (MM) at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting taking place in Chicago and virtually June 3-7, 2022. Read More

Demo Live Account See Partner Details

Content Topics

Lava

Therapeutics

Present

Updated

051 Clinical

Data

Lava 051

American

Society

Oncology

asco

Annual

Meeting

Stock

LVTX

Posted: Apr 27 2022, 10:05

Author Name: GlobeNewsWire

LVTX News

By GlobeNewsWire
September 6, 2023

LAVA Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference

UTRECHT, The Netherlands and PHILADELPHIA, Sept. 06, 2023 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. ( Nasdaq: LVTX ), an immuno-oncology company focu

By Zacks Investment Research
August 22, 2023

LAVA Therapeutics N.V. (LVTX) Reports Q2 Loss, Tops Revenue Estimates

LAVA Therapeutics N.V. (LVTX) came out with a quarterly loss of $0.48 per share in line with the Zacks Consensus Estimate.

By Zacks Investment Research
November 25, 2022

Can LAVA Therapeutics N.V. (LVTX) Climb 198% to Reach the Level Wall Street Analysts Expect?

The mean of analysts' price targets for LAVA Therapeutics N.V. (LVTX) points to a 197.6% upside in the stock.

By Zacks Investment Research
November 16, 2022

LAVA Therapeutics N.V. (LVTX) Q3 Earnings Surpass Estimates

LAVA Therapeutics N.V. (LVTX) delivered earnings and revenue surprises of 157.14% and 38.96%, respectively, for the quarter ended September 2022.

By GlobeNewsWire
September 7, 2022

LAVA Therapeutics to Present at the H.C. Wainwright 24th Annual Global Investment Conference

UTRECHT, The Netherlands and PHILADELPHIA, Sept. 07, 2022 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (Nasdaq: LVTX), a clinical stage immuno-oncology

By GlobeNewsWire
May 5, 2022

LAVA Therapeutics to Participate at the UBS Global Healthcare Conference

UTRECHT, The Netherlands and PHILADELPHIA, May 05, 2022 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (Nasdaq: LVTX), an immuno-oncology company focused

By GlobeNewsWire
April 27, 2022

LAVA Therapeutics to Present Updated LAVA-051 Clinical Data at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

UTRECHT, The Netherlands and PHILADELPHIA, April 27, 2022 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. ( Nasdaq: LVTX ), an immuno-oncology company focu

By Benzinga
March 7, 2022

LAVA Therapeutics Shares Interim LAVA-051 Data From Early-Stage Cancer Trial

LAVA Therapeutics NV (NASDAQ: LVTX) announced initial data from its first clinical study with LAVA-051. The presentation will include data from t

Risk Disclosure:

Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
We would like to remind you that the data contained in this website is not necessarily real-time nor accurate.
The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. We and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of us and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. We may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.